Genesis Biotechnology Group

www.genesisbiotechgroup.com

The Genesis Biotechnology Group is a consortium of vertically integrated corporate entities, which facilitate the overall market implementation and delivery of basic science products such as diagnostic assays and drug discovery.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

ENSYSCE, A CALIFORNIA BASED BIOTECH COMPANY WITH A MISSION TO SOLVE THE OPIOID CRISIS, EXPLORING A TREATMENT FOR COVID-19

TheDailyTimes | April 15, 2020

news image

Ensysce Biosciences announced that it is exploring the opportunity to initiate a clinical trial of oral Nafamostat, an ingredient from its opioid overdose protection platform, as a treatment for COVID-19. The goal is to evaluate if nafamostat mesylate (Nafamostat), a synthetic protease inhibitor will be effective in preventing or reducing the lethal outcome of COVID-19 infection. Currently, there are no approved drugs to manage infection with SARS-CoV-2 and nafamostat has shown promise in severa...

Read More

INDUSTRIAL IMPACT

SHOUTI INTRODUCES BASECAMP BIO AS A WHOLLY OWNED SUBSIDIARY TO EXPAND PIPELINE AND PARTNERSHIPS

ShouTi Inc | February 18, 2022

news image

ShouTi Inc., a clinical-stage global biopharmaceutical company developing novel oral therapeutics to treat a wide range of chronic diseases, today introduced Basecamp Bio, a wholly owned subsidiary dedicated to fueling ShouTi’s pipeline and pursuing drug discovery partnerships. Basecamp Bio integrates unique insights, skills, technological know-how and experience to navigate the complex challenges of membrane protein structure-based drug discovery. Its mission is to prosecut...

Read More

INDUSTRIAL IMPACT, MEDICAL

SENSIBLE BIOTECHNOLOGIES ANNOUNCES PARTNERSHIP WITH GINKGO BIOWORKS TO DEVELOP NOVEL MRNA MANUFACTURING PLATFORM

prnewswire | April 04, 2023

news image

Sensible Biotechnologies, an early stage biotechnology company, today announced a partnership to develop an in vivo microbial mRNA manufacturing platform with Ginkgo Bioworks which is building the leading platform for cell programming and biosecurity. Today, the vast majority of mRNA used in vaccines, therapeutics and other applications is produced by in vitro transcription (IVT), a cell-free process, which is driven by purified enzymes. In conventional mRNA manufacturing, produ...

Read More

INDUSTRIAL IMPACT

PROVIDENCE THERAPEUTICS SIGNS LICENSING AGREEMENT WITH SICKKIDS FOR IMMUNOTARGETING TECHNOLOGY

Providence Therapeutics | July 13, 2022

news image

Providence Therapeutics, Canada's premier mRNA medicines company, is pleased to announce that it has entered into an exclusive licensing agreement with The Hospital for Sick Children of Toronto, ON, for an immunotargeting technology platform. This platform provides an innovative approach to generating adjuvant-free vaccines and works by targeting Antigen Presenting Cells of the immune system via the MHC Class II molecules on their surface. This can result in an enhanced immune response to an...

Read More
news image

ENSYSCE, A CALIFORNIA BASED BIOTECH COMPANY WITH A MISSION TO SOLVE THE OPIOID CRISIS, EXPLORING A TREATMENT FOR COVID-19

TheDailyTimes | April 15, 2020

Ensysce Biosciences announced that it is exploring the opportunity to initiate a clinical trial of oral Nafamostat, an ingredient from its opioid overdose protection platform, as a treatment for COVID-19. The goal is to evaluate if nafamostat mesylate (Nafamostat), a synthetic protease inhibitor will be effective in preventing or reducing the lethal outcome of COVID-19 infection. Currently, there are no approved drugs to manage infection with SARS-CoV-2 and nafamostat has shown promise in severa...

Read More
news image

INDUSTRIAL IMPACT

SHOUTI INTRODUCES BASECAMP BIO AS A WHOLLY OWNED SUBSIDIARY TO EXPAND PIPELINE AND PARTNERSHIPS

ShouTi Inc | February 18, 2022

ShouTi Inc., a clinical-stage global biopharmaceutical company developing novel oral therapeutics to treat a wide range of chronic diseases, today introduced Basecamp Bio, a wholly owned subsidiary dedicated to fueling ShouTi’s pipeline and pursuing drug discovery partnerships. Basecamp Bio integrates unique insights, skills, technological know-how and experience to navigate the complex challenges of membrane protein structure-based drug discovery. Its mission is to prosecut...

Read More
news image

INDUSTRIAL IMPACT, MEDICAL

SENSIBLE BIOTECHNOLOGIES ANNOUNCES PARTNERSHIP WITH GINKGO BIOWORKS TO DEVELOP NOVEL MRNA MANUFACTURING PLATFORM

prnewswire | April 04, 2023

Sensible Biotechnologies, an early stage biotechnology company, today announced a partnership to develop an in vivo microbial mRNA manufacturing platform with Ginkgo Bioworks which is building the leading platform for cell programming and biosecurity. Today, the vast majority of mRNA used in vaccines, therapeutics and other applications is produced by in vitro transcription (IVT), a cell-free process, which is driven by purified enzymes. In conventional mRNA manufacturing, produ...

Read More
news image

INDUSTRIAL IMPACT

PROVIDENCE THERAPEUTICS SIGNS LICENSING AGREEMENT WITH SICKKIDS FOR IMMUNOTARGETING TECHNOLOGY

Providence Therapeutics | July 13, 2022

Providence Therapeutics, Canada's premier mRNA medicines company, is pleased to announce that it has entered into an exclusive licensing agreement with The Hospital for Sick Children of Toronto, ON, for an immunotargeting technology platform. This platform provides an innovative approach to generating adjuvant-free vaccines and works by targeting Antigen Presenting Cells of the immune system via the MHC Class II molecules on their surface. This can result in an enhanced immune response to an...

Read More